Infliximab-Induced Lupus in Crohn's Disease / 대한내과학회지
Korean Journal of Medicine
;
: 303-307, 2019.
Article
in Korean
| WPRIM
| ID: wpr-759930
ABSTRACT
Infliximab (IFX) is an anti-tumor necrosis factor (TNF) monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. Rarely, anti-TNF-induced lupus (ATIL) may occur. ATIL differs from classical drug-induced lupus. We report a 49-year-old woman who developed polyarthralgia after 2 years of IFX treatment for Crohn's disease. Based on the autoantibody profiles, ATIL was diagnosed and low-dose glucocorticoid, hydroxychloroquine, and celecoxib were prescribed. However, arthralgia and hemolytic anemia developed. Because the anti-dsDNA titers waxed and waned, she was switched to vedolizumab, a monoclonal antibody to the human lymphocyte α4β7 integrin. Six months after switching treatment, the arthralgia had improved and the anti-dsDNA antibody normalized. Here, we report a case of ATIL that resolved after switching from infliximab to vedolizumab.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Arthritis, Rheumatoid
/
Spondylitis, Ankylosing
/
Lymphocytes
/
Crohn Disease
/
Arthralgia
/
Celecoxib
/
Infliximab
/
Hydroxychloroquine
/
Anemia, Hemolytic
/
Lupus Erythematosus, Systemic
Limits:
Female
/
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS